Sensex
83,739.13 profit arw 2,072.67 (2.54%)
Nifty
25,727.55 profit arw 639.15 (2.55%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 03-Feb-2026
Corporate News
03-Feb-2026     19:01

NATCO Pharma receives USFDA tentative approval for Erdafitinib tablets

NATCO Pharma received tentative approval from the USFDA for Erdafitinib, 3 mg, 4mg, and 5 mg, a generic version of Balversa' by Janssen Biotech Inc.

NATCO's Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations who have disease progression during at least 1 line of prior therapy.

Erdafitinib tablets had estimated sales of approximately USD 60 million in the U.S. for 12 months ending Sep'25 as per industry sales data.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

83,739.13 2,072.67 (2.54%)

Nifty

25,727.55 639.15 (2.55%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

26,834.78 59.20(0.22%)